LawrenceEdgarFlahertyMD

Oncology • Detroit, MI

Professor, Internal Medicine, Wayne State University School of Medicine

Join to view full profile

Dr. Flaherty is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Flaherty's full profile

Already have an account?

Office
Karmanos Cancer Center
4100 John R Hwcrc 4th Fl
Detroit, MI 48201
Phone+1 313-576-8779

Fax+1 313-576-8726
Is this information wrong?

Education & Training

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1983 - 1986
Medical College of Wisconsin Affiliated HospitalsResidency, Internal Medicine, 1978 - 1981
Saint Louis University School of MedicineClass of 1978

Certifications & Licensure

MI State Medical License 1986 - 2026
PA State Medical License 1984 - 1988
WI State Medical License 1979 - 1983
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com
Top MD Consumers Checkbook

Clinical Trials

Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma Start of enrollment: 1997 Nov 13
Completed
Phase 3
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma Start of enrollment: 1999 Mar 25
Active, not recruiting
Phase 3
S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma Start of enrollment: 2000 Aug 01
Completed
Phase 3
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2/Neu-Negative Metastatic Breast Cancer Start of enrollment: 2010 Mar 08
Terminated
Phase 2
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3
Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery Start of enrollment: 2010 Jul 01
Terminated
Phase 2
Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2011 Jan 18
Completed
Phase 2
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma Start of enrollment: 2012 Jun 03
Completed
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Start of enrollment: 2012 Aug 01
Terminated
Phase 4
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Start of enrollment: 2013 Jul 12
Completed
Phase 3
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Start of enrollment: 2013 May 01
Terminated
Phase 4
Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic Start of enrollment: 2014 May 01
Completed
Phase 2
Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2014 Sep 19
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

2 citations
An Open–Label, Randomized, Multi–Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin–2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma
Merve Hasanov, Denái R. Milton, William H. Sharfman, Bret Taback, Lee D. Cranmer, Gregory A. Daniels, Lawrence E. Flaherty, Sigrun Hallmeyer, Mohammed M. Milhem, Lynn ...> ;Oncoimmunology. 2021 Oct 9
13 citations
Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0-2+) metastatic br...
Lawrence G. Lum, Zaid S. Al-Kadhimi, Abhinav Deol, Vidya Kondadasula, Dana L Schalk, Elyse Tomashewski, Patricia A. Steele, Kristie Fields, Melissa Giroux, Qin Liu, La...> ;Journal for Immunotherapy of Cancer. 2021 Jun 1
10 citations
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis.
Ahmad A. Tarhini, Ni Kang, Sandra J. Lee, F. Stephen Hodi, Gary I. Cohen, Omid Hamid, Laura F. Hutchins, Jeffrey A. Sosman, Harriet M. Kluger, Zeynep Eroglu, Henry B. ...> ;Journal for Immunotherapy of Cancer. 2021 May 1
17 citations
Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastases.
Gino K. In, Kelsey Poorman, Michelle Saul, Steven J. O'Day, Jeffrey M. Farma, Anthony J. Olszanski, Michael S. Gordon, Jacob Stephen Thomas, Burton L. Eisenberg, Lawre...> ;Oncotarget. 2020 Aug 18
91 citations
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609
Ahmad A. Tarhini, Sandra J. Lee, F. Stephen Hodi, Uma N. M. Rao, Gary I. Cohen, Omid Hamid, Laura F. Hutchins, Jeffrey A. Sosman, H. Kluger, Zeynep Eroglu, Henry B. Ko...> ;Journal of Clinical Oncology. 2020 Feb 20
24 citations
Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution.
Ammar Sukari, Misako Nagasaka, Roba Alhasan, Dhaval Patel, Antoinette J. Wozniak, Radhakrishnan Ramchandren, Ulka N. Vaishampayan, Amy Weise, Lawrence E. Flaherty, Hye...> ;Anticancer Research. 2019 Feb 1
15 citations
A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma
Joseph I. Clark, Jatinder Singh, Marc S. Ernstoff, Christopher D. Lao, Lawrence E. Flaherty, Theodore F. Logan, Brendan D. Curti, Sanjiv S. Agarwala, Bret Taback, Lee ...> ;Journal for Immunotherapy of Cancer. 2018 Jul 27
364 citations
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3...
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,...> ;The Lancet. Oncology. 2017 Dec 1
23 citations
High frequency of brain metastases after adjuvant therapy for high-risk melanoma.
Wolfram E. Samlowski, James C. Moon, Merle Witter, Michael B. Atkins, John M. Kirkwood, Megan Othus, Antoni Ribas, Vernon K. Sondak, Lawrence E. Flaherty> ;Cancer Medicine. 2017 Oct 10
36 citations
Phase III randomized study of 4 weeks of high-dose interferon-α-2b in stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) melanoma: A trial of the Eastern Coop...
Sanjiv S. Agarwala, Sandra J. Lee, Wai-Ki Yip, Uma N. M. Rao, Ahmad A. Tarhini, Gary I. Cohen, Douglas S. Reintgen, Terry L. Evans, Joanna M. Brell, Mark R. Albertini,...> ;Journal of Clinical Oncology. 2017 Jan 30
71 citations
Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933
Sylvia Lee, James C. Moon, Bruce G. Redman, Tarek Chidiac, Lawrence E. Flaherty, Yuanyuan Zha, Megan Othus, Antoni Ribas, Vernon K. Sondak, Thomas F. Gajewski, Kim Mar...> ;Cancer. 2015 Feb 1
70 citations
SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer
George Thomas Budd, William E. Barlow, Halle C. F. Moore, Timothy J. Hobday, James A. Stewart, Claudine Isaacs, Muhammad Salim, Jonathan K. Cho, Kristine Rinn, Kathy S...> ;Journal of Clinical Oncology. 2015 Jan 1
77 citations
Southwest Oncology Group S0008: A Phase III Trial of High-Dose Interferon Alfa-2b Versus Cisplatin, Vinblastine, and Dacarbazine, Plus Interleukin-2 and Interferon in ...
Lawrence E. Flaherty, Megan Othus, Michael B. Atkins, Ralph J. Tuthill, John A. Thompson, John T. Vetto, Frank G. Haluska, Alberto S. Pappo, Jeffrey A. Sosman, Bruce G...> ;Journal of Clinical Oncology. 2014 Nov 20
6 citations
New Options for the Adjuvant Treatment of Cutaneous Melanoma
Amy Weise, Lawrence E. Flaherty> ;Current Oncology Reports. 2014 Oct 7
8 citations
Adjuvant Vaccine Immunotherapy of Resected, Clinically Node-Negative Melanoma: Long-term Outcome and Impact of HLA Class I Antigen Expression on Overall Survival
William E. Carson, Joseph M. Unger, Jeffrey A. Sosman, Lawrence E. Flaherty, Ralph J. Tuthill, Mark J. Porter, John A. Thompson, Raymond A. Kempf, Megan Othus, Antoni ...> ;Cancer Immunology Research. 2014 Jul 3
179 citations
Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study
Antoni Ribas, Rene Gonzalez, Anna C. Pavlick, Omid Hamid, Thomas F. Gajewski, Adil Daud, Lawrence E. Flaherty, Theodore F. Logan, Bartosz Chmielowski, Karl D. Lewis, D...> ;The Lancet. Oncology. 2014 Aug 1
40 citations
A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States.
Lawrence E. Flaherty, Omid Hamid, Gerald P. Linette, Lynn M. Schuchter, Sigrun Hallmeyer, Rene Gonzalez, C. Lance Cowey, Anna C. Pavlick, Fred J. Kudrik, Brendan D. Cu...> ;Cancer Journal. 2014 Jan 1
154 citations
Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma
Keith T. Flaherty, Sandra J. Lee, Fengmin Zhao, Lynn M. Schuchter, Lawrence E. Flaherty, Richard F. Kefford, Michael B. Atkins, Philip D. Leming, John M. Kirkwood> ;Journal of Clinical Oncology. 2013 Jan 20
114 citations
A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430.
Jeffrey A. Sosman, James J. Moon, Ralph J. Tuthill, James Warneke, John T. Vetto, Bruce G. Redman, Poching Liu, Joseph M. Unger, Lawrence E. Flaherty, Vernon K. Sondak> ;Cancer. 2011 Oct 15
58 citations
Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438)
Kim Margolin, James C. Moon, Lawrence E. Flaherty, Christopher D. Lao, Wallace Akerley, Megan Othus, Jeffrey A. Sosman, John M. Kirkwood, Vernon K. Sondak> ;Clinical Cancer Research. 2012 Feb 15
49 citations
A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer
Elaina M. Gartner, Paula Silverman, Michael S. Simon, Lawrence E. Flaherty, Judith Abrams, Percy Ivy, Patricia LoRusso> ;Breast Cancer Research and Treatment. 2012 Feb 1
3 citations
SWOG S0215: A Phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer
Robert B. Livingston, William E. Barlow, Joseph J. Kash, Kathy S. Albain, Julie R. Gralow, Danika L. Lew, Lawrence E. Flaherty, Melanie Royce, Gabriel N. Hortobagyi> ;Breast Cancer Research and Treatment. 2011 Aug 9
19 citations
Targeted therapies: Improved outcomes for patients with metastatic melanoma
Vernon K. Sondak, Lawrence E. Flaherty> ;Nature Reviews. Clinical Oncology. 2011 Jul 26
The effect of smoking history on response and survival outcomes patients with in esophageal cancer treated with neoadjuvant concurrent chemoradiotherapy followed by su...
Salerno May K, Malik NK, Yang G, Patil S, Flaherty L, Khushalani NI, Sher T, Yendamuri SS, Nava HR, Warren GW> ;J. Clin. Oncol.. 2011-05-20
Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate- and high-risk melanoma (Intergroup trial E 1...
Agarwala SS, Lee SJ, Flaherty LE, Smylie M, Kefford RF, Carson WE, Cohen G, Kirkwood JM> ;J. Clin. Oncol.. 2011-05-20
Join now to see all